Table 4.

Comparison of clinical and pathologic manifestations in patients with IgAN according to rare variants in CFHR5

CharacteristicsTotal, n=500Potential Pathogenic VariantsP Valuea
With, n=43Without, n=457
Baseline
 Age, yr, mean±SD34.23±11.0933.72±11.7134.27±11.050.75
 Men258 (51.60%)23 (53.50%)235 (51.40%)0.79
 Hypertension0.94
  With hypertension68 (13.62%)6 (14.00%)62 (13.60%)
  Without hypertension432 (86.38%)37 (86.00%)395 (86.40%)
 Initial proteinuria, g/d, median (IQR)1.42 (0.81, 2.66)1.40 (0.83, 2.51)1.43 (0.80, 2.72)0.92
  <1168 (33.60%)14 (32.60%)154 (33.70%)
  1–3.5253 (50.60%)22 (51.20%)231 (50.50%)
   ≥3.579 (15.80%)7 (16.20%)72 (15.80%)
 eGFR, ml/min per 1.73 m2, mean±SD84.19±27.0382.13±22.4084.39±27.430.60
 Haas classification0.43b
  143 (8.60%)3 (7.00%)40 (8.80%)
  24 (0.80%)0 (0.00%)4 (0.90%)
  3226 (45.20%)18 (41.90%)208 (45.50%)
  4166 (33.20%)16 (37.10%)150 (32.80%)
  561 (12.20%)6 (14.00%)55 (12.00%)
 Serum IgA level, g/L, mean±SD3.34±1.223.29±1.533.35±1.190.77
 Serum C3 level, g/L, mean±SD1.04±0.281.11±0.391.04±0.270.14
 IgA deposition (1+/2+/3+–4+)14 (2.80%)/78 (15.60%)/408 (81.60%)1 (2.30%)/9 (20.90%)/33 (76.70%)13 (2.80%)/69 (15.10%)/375 (82.10%)0.52c
 C3 deposition (−/1+/2+/3+–4+)41 (8.20%)/57 (11.40%)/164 (32.80%)/238 (47.60%)5 (11.60%)/5 (11.60%)/19 (44.20%)/14 (32.60%)36 (7.90%)/52 (11.40%)/145 (31.70%)/224 (49.00%)0.11c
 Ratio of glomeruli with crescents (IQR)0.05 (0.00, 0.15)0.04 (0.00, 0.12)0.05 (0.00, 0.16)0.39
Follow-up
 Follow-up time, mo, mean±SD56.26±36.6162.51±37.3555.67±31.000.17
 Prednisone/immunosuppressive agents208 (41.60%)19 (44.20%)189 (41.40%)0.72
 ARBs/ACE inhibitors483 (96.60%)43 (100%)440 (96.30%)0.40
 Time average proteinuria, g/d, median (IQR)0.75 (0.44, 1.41)0.71 (0.37, 1.70)0.77 (0.44, 1.38)0.95
 Slope, ml/min per mo, median (IQR)−0.20 (−0.51, 0.00)−0.17 (−0.53, −0.10)−0.20 (−0.51, 0.00)0.80
 Composite events, no.84 (16.80%)10 (23.30%)74 (16.20%)0.24
  • IQR, interquartile range; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme.

  • a The P value was used to indicate the difference between with and without potential pathogenic variants group.

  • b The P value was calculated between Haas 1–3 and Haas 4–5.

  • c The P value was calculated by linear-by-linear association.